PanoramicaGraficoProfiloStatistiche chiaveDati finanziariNotizie
Derivati
SchermataTrader

ARGENX SE EO -,10/  NL0010832176  /

München
15/11/2024  08:13:34 Var. -2.60 Volume Denaro21:59:29 Lettera21:59:29 Capitalizzazione di mercato Dividend Y. Rapporto P/E
564.20EUR -0.46% 0
Fatturato: 0.00		 -Quantità in denaro: - -Quantità in lettera: - 32.12 bill.EUR - -
GlobeNewswire 28/08 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 26/08 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...
GlobeNewswire 12/08 Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire 25/07 argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
GlobeNewswire 18/07 argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 202...
GlobeNewswire 16/07 argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Ge...
GlobeNewswire 08/07 Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
GlobeNewswire 25/06 argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire 21/06 argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...
GlobeNewswire 17/06 argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...
GlobeNewswire 13/06 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
GlobeNewswire 04/06 argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire 09/05 argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 07/05 argenx announces results of Annual General Meeting of Shareholders
GlobeNewswire 07/05 argenx to Present at BofA Securities 2024 Health Care Conference
GlobeNewswire 02/05 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
GlobeNewswire 16/04 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...
GlobeNewswire 27/03 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GlobeNewswire 26/03 argenx Announces Annual General Meeting of Shareholders on May 7, 2024
GlobeNewswire 26/03 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...
GlobeNewswire 07/03 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...
GlobeNewswire 29/02 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
GlobeNewswire 26/02 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 22/02 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...
GlobeNewswire 20/02 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...